Dynamic regulation of pituitary mRNAs for bone morphogenetic protein (BMP) 4, BMP receptors, and activin/inhibin subunits in the ewe during the estrous cycle and in cultured pituitary cells.
Recently, bone morphogenetic protein (BMP) 4 has been shown to inhibit FSH secretion in ewe. The detection of BMP4 mRNA and BMP receptors in the pituitary suggests that BMP4 can exert paracrine actions on FSH production. This work aimed at determining whether BMP4 and/or BMP receptor mRNA as well as activin/inhibin subunit mRNA fluctuates during the estrous cycle when FSHβ mRNA and FSH release changed. The estrous cycles of ewes were synchronized with progestagen sponges. Ewes were killed in late follicular stage (n=5), before the secondary FSH surge (n=4), and in luteal phase (n=4). Using quantitative reverse transcription-PCR, we showed that the levels of mRNA for BMP4, BMP receptor, the inhibitor of differentiation 2 (Id2), a target gene of BMP4, and noggin did not change significantly across the estrous cycle. In contrast, the level of activin βB mRNA and the percentage of immunoreactive cells for activin βB-subunit were higher before the secondary surge of FSH compared to other groups. In ewe pituitary cell cultures, activin, GnRH, or estradiol-17β (E(2)) did not significantly affect the levels of BMP4, BMP receptor, and Id2 mRNA. E(2), but not GnRH, increased the level of activin βB mRNA. Moreover, the in vitro FSH release was not modified by noggin, a BMP antagonist. In contrast, SB431542, an inhibitor of activin pathway, inhibited FSH release. Collectively, our data showed that pituitary BMP4 would not play a crucial role in the regulation of FSH production during the estrous cycle, whereas local activin B would be a major stimulus of FSH synthesis necessary for the secondary FSH surge.
Sallon
C
C
Centre INRA de Tours, UMR85 Physiologie de la Reproduction et des Comportements, Nouzilly, France.
Faure
M O
MO
Fontaine
J
J
Taragnat
C
C
D028341:Activins / Q000737:chemistry / Q000235:genetics* / Q000494:pharmacology; D000818:Animals; D001483:Base Sequence; D001549:Benzamides / Q000494:pharmacology; D055415:Bone Morphogenetic Protein 4 / Q000235:genetics*; D052004:Bone Morphogenetic Protein Receptors / Q000235:genetics*; D002352:Carrier Proteins / Q000494:pharmacology; D002478:Cells, Cultured; D017931:DNA Primers / Q000235:genetics; D004149:Dioxoles / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D004971:Estrus / Q000235:genetics* / Q000502:physiology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D037201:Follicle Stimulating Hormone, beta Subunit / Q000235:genetics; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D021122:Protein Subunits; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012756:Sheep / Q000235:genetics* / Q000502:physiology*; D015533:Transcriptional Activation / Q000187:drug effects; D000099176:Noggin Protein
D028341:Activins; D001549:Benzamides; D055415:Bone Morphogenetic Protein 4; D052004:Bone Morphogenetic Protein Receptors; D002352:Carrier Proteins; D017931:DNA Primers; D004149:Dioxoles; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D037201:Follicle Stimulating Hormone, beta Subunit; D007987:Gonadotropin-Releasing Hormone; D021122:Protein Subunits; D012333:RNA, Messenger; D000099176:Noggin Protein; C459179:4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide